Therapeutic Antibodies

AGENT TARGET CLINICAL USE NOTES
Cancer therapy      
Alemtuzumab CD52 CLL, MS “Alymtuzumab”—chronic lymphocytic leukemia
Bevacizumab VEGF Colorectal cancer, renal cell carcinoma, non-small cell lung cancer Also used for neovascular age-related macular degeneration, proliferative diabetic retinopathy, and macular edema
Cetuximab EGFR Stage IV colorectal cancer, head and neck cancer  
Rituximab CD20 B-cell non-Hodgkin lymphoma, CLL, rheumatoid arthritis, ITP, multiple sclerosis  
Trastuzumab HER2 Breast cancer, gastric cancer HER2—“tras2zumab”
Autoimmune disease therapy      
Adalimumab, certolizumab, golimumab, infliximab Soluble TNF-α IBD, rheumatoid arthritis, ankylosing spondylitis, psoriasis Etanercept is a decoy TNF-α receptor and not a monoclonal antibody
Daclizumab CD25 (part of IL-2 receptor) Relapsing multiple sclerosis  
Eculizumab Complement protein C5 Paroxysmal nocturnal hemoglobinuria  
Natalizumab α4-integrin Multiple sclerosis, Crohn disease α4-integrin: WBC adhesion Risk of PML in patients with JC virus
Ustekinumab IL-12/IL-23 Psoriasis, psoriatic arthritis  
Other applications      
Abciximab Platelet glycoproteins IIb/IIIa Antiplatelet agent for prevention of ischemic complications in patients undergoing percutaneous coronary intervention IIb times IIIa equals “absiximab”
Denosumab Binds receptor activator NFkB, blocks interaction between RANKL  and RANK Osteoporosis; inhibits osteoclast maturation (mimics osteoprotegerin) Denosumab affects osteoclasts
Digoxin immune Fab Digoxin Antidote for digoxin toxicity  
Omalizumab IgE Refractory allergic asthma; prevents IgE binding to FcεRI  
Palivizumab RSV F protein RSV prophylaxis for high-risk infants PaliVIzumab—VIrus

Filipino MD

An independent organization catered to bringing enriching opportunities to doctors, researchers and medical institutions.

TERMS OF SERVICE
ADVERTISE
administrator@filipinomd.com

Like Us On Facebook

Facebook Pagelike Widget

You cannot copy the contents of this page.